Literature DB >> 31799869

Gadolinium Retention and Breast MRI Screening: More Harm Than Good?

Francesco Sardanelli1,2, Andrea Cozzi1, Rubina Manuela Trimboli1, Simone Schiaffino2.   

Abstract

OBJECTIVE. The purpose of this article is to describe the risk-benefit balance of contrast-enhanced breast MRI (CE-BMRI) screening. CONCLUSION. CE-BMRI confers risk of effects associated with administration of gadolinium-based contrast agents (GBCAs), including nephrogenic systemic fibrosis and gadolinium retention. The risk-benefit balance of CE-BMRI screening is favorable for carriers of BRCA, TP53, or other deleterious mutations women who have undergone thoracic irradiation; and women at 20% or greater lifetime risk of breast cancer. The balance is uncertain, however, for women at intermediate to average risk. Women must always receive detailed information regarding possible GBCA-associated effects.

Entities:  

Keywords:  MRI; breast neoplasms; contrast media; gadolinium; nephrogenic systemic fibrosis

Mesh:

Substances:

Year:  2019        PMID: 31799869     DOI: 10.2214/AJR.19.21988

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  Breast cancer screening: in the era of personalized medicine, age is just a number.

Authors:  Andrea Cozzi; Simone Schiaffino; Paolo Giorgi Rossi; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2020-12

2.  MR Enterography in Crohn's Disease: Comparison of Contrast Imaging with Diffusion-weighted Imaging and a special Form of Color Coding.

Authors:  Maja Jakob; Maik Backes; Christian Schaefer; Joerg Albert; Angela Geissler
Journal:  Rofo       Date:  2022-06-15

Review 3.  Hereditary diffuse gastric cancer: updated clinical practice guidelines.

Authors:  Vanessa R Blair; Maybelle McLeod; Fátima Carneiro; Daniel G Coit; Johanna L D'Addario; Jolanda M van Dieren; Kirsty L Harris; Nicoline Hoogerbrugge; Carla Oliveira; Rachel S van der Post; Julie Arnold; Patrick R Benusiglio; Tanya M Bisseling; Alex Boussioutas; Annemieke Cats; Amanda Charlton; Karen E Chelcun Schreiber; Jeremy L Davis; Massimiliano di Pietro; Rebecca C Fitzgerald; James M Ford; Kimberley Gamet; Irene Gullo; Richard H Hardwick; David G Huntsman; Pardeep Kaurah; Sonia S Kupfer; Andrew Latchford; Paul F Mansfield; Takeshi Nakajima; Susan Parry; Jeremy Rossaak; Haruhiko Sugimura; Magali Svrcek; Marc Tischkowitz; Toshikazu Ushijima; Hidetaka Yamada; Han-Kwang Yang; Adrian Claydon; Joana Figueiredo; Karyn Paringatai; Raquel Seruca; Nicola Bougen-Zhukov; Tom Brew; Simone Busija; Patricia Carneiro; Lynn DeGregorio; Helen Fisher; Erin Gardner; Tanis D Godwin; Katharine N Holm; Bostjan Humar; Caroline J Lintott; Elizabeth C Monroe; Mark D Muller; Enrique Norero; Yasmin Nouri; Joana Paredes; João M Sanches; Emily Schulpen; Ana S Ribeiro; Andrew Sporle; James Whitworth; Liying Zhang; Anthony E Reeve; Parry Guilford
Journal:  Lancet Oncol       Date:  2020-08       Impact factor: 41.316

4.  Forewarned Is Forearmed: Can Better Patient Counseling Increase MRI Utilization in High-Risk Women?

Authors:  Amy E Cyr; Ranjna Sharma
Journal:  Ann Surg Oncol       Date:  2020-08-09       Impact factor: 5.344

5.  Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting.

Authors:  Sean A Woolen; Jonathan P Troost; Shokoufeh Khalatbari; Akshat C Pujara; Jennifer S McDonald; Robert J McDonald; Prasad Shankar; Alana A Lewin; Amy N Melsaether; Steven M Westphal; Katherine H Patterson; Ashley Nettles; John P Welby; Parth Pradip Patel; Neud Kiros; Lisa Piccoli; Matthew S Davenport
Journal:  Eur Radiol       Date:  2021-05-28       Impact factor: 5.315

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.